The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
In plain words A Phase 2 study of thymopentin in people 75 and older, run by Second Affiliated Hospital of Soochow University. It plans to enroll about 29 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 75 and older. Conditions: Carcinoma; Solid Tumor.
- Aged 75 years and above
- Standard treatment is ineffective (disease progresses after treatment) or locally advanced or metastatic malignant solid tumor patients who cannot tolerate standard therapy, cannot receive or do not have standard therapy
- ECOG(Eastern Cooperative Oncology Group) performance is 0-3
- Life expectancy greater than 3 months
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin
Registered summary
This is an open-label, single-arm, Phase II investigator-initiated trial of hypofractionated radiotherapy combined with PD-L1 inhibitor sequential GM-CSF and thymopentin for treatment of elderly patients with advanced solid tumors, when the HER-2 positive patients are treated with extra antibody-drug conjugate.
Where, as registered
No US site; China (1).